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Diverse matrix metalloproteinase functions
regulate cancer amoeboid migration
Jose L. Orgaz1, Pahini Pandya1, Rimple Dalmeida1,*, Panagiotis Karagiannis2,*, Berta Sanchez-Laorden3,*,
Amaya Viros3, Jean Albrengues4, Frank O. Nestle2, Anne J. Ridley5, Cedric Gaggioli4, Richard Marais3,
Sophia N. Karagiannis2 & Victoria Sanz-Moreno1
Rounded-amoeboid cancer cells use actomyosin contractility driven by Rho-ROCK and JAK-
STAT3 to migrate efficiently. It has been suggested that rounded-amoeboid cancer cells do
not require matrix metalloproteinases (MMPs) to invade. Here we compare MMP levels in
rounded-amoeboid and elongated-mesenchymal melanoma cells. Surprisingly, we find that
rounded-amoeboid melanoma cells secrete higher levels of several MMPs, including
collagenase MMP-13 and gelatinase MMP-9. As a result, rounded-amoeboid melanoma cells
degrade collagen I more efficiently than elongated-mesenchymal cells. Furthermore, using a
non-catalytic mechanism, MMP-9 promotes rounded-amoeboid 3D migration through
regulation of actomyosin contractility via CD44 receptor. MMP-9 is upregulated in a panel of
rounded-amoeboid compared with elongated-mesenchymal melanoma cell lines and its
levels are controlled by ROCK-JAK-STAT3 signalling. MMP-9 expression increases during
melanoma progression and it is particularly prominent in the invasive fronts of lesions, cor-
relating with cell roundness. Therefore, rounded-amoeboid cells use both catalytic and non-
catalytic activities of MMPs for invasion.
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C
ancer cells can use different modes to invade through the
extracellular matrix (ECM) depending on adhesion1,
actomyosin contractility2, Rho-family GTPases3,4 and
composition of the ECM5. Single migrating cells can use a
mesenchymal-type of movement in which cells are more
elongated4,6 and display Rac-driven actin-rich protrusions4,6–8.
In rounded-amoeboid movement, cells move with high levels of
actomyosin contractility driven by Rho-Rho kinase (ROCK)
signalling4,6,9. ROCK decreases myosin phosphatase activity,
increasing phosphorylation of the regulatory myosin light chain 2
(MLC2) and activity of myosin II (ref. 10). JAK1 signalling
cooperates with ROCK to promote high actomyosin
contractility9,11–13. Interestingly, elongated-mesenchymal cells
treated with protease inhibitors ‘round up’ and keep moving
and invading, which has been proposed as a mesenchymal-to-
amoeboid transition14–16. These results led to the interpretation
that rounded-amoeboid invasion is independent of pericellular
proteases. However, matrix degradation has been reported using
3D collagen I systems after observation of tracks left by rounded-
amoeboid cancer cells17. Here we show that rounded-amoeboid
cells secrete and utilize matrix metalloproteinases (MMPs) to
invade through collagen I. In particular, we find that MMP-9 is
upregulated in rounded-amoeboid cells through ROCK-JAK-
STAT3 signalling, and its expression increases during melanoma
progression and in the invasive fronts of melanoma lesions,
enriched of rounded-amoeboid cells. Furthermore, we show that
MMP-9 promotes rounded-amoeboid 3D migration using a non-
catalytic mechanism through regulation of actomyosin
contractility via CD44 receptor.
Results
Rounded-amoeboid cells produce MMPs on collagen matrices.
Rounded-amoeboid cells use actomyosin contractility to achieve
high migratory speeds compared with elongated-mesenchymal
cells4,9,18,19. It has been shown that in the presence of protease
inhibitors, mesenchymal-like cancer cells can acquire amoeboid
type of migration/invasion8,14–16,20. We therefore wanted to
compare the MMP levels of rounded-amoeboid and more
elongated-mesenchymal cells.
A375M2 is a metastatic and invasive melanoma sub-line derived
from A375P cells4,19,21. A375M2 sub-line was selected to colonize
the lung efficiently in vivo and was shown to overexpress RhoC
compared with A375P cells21, which could in part explain how
A375M2 cells have higher actomyosin activity4,19. We compared cell
morphologies of A375M2 cells and A375P melanoma cells grown on
atelopeptide bovine dermal collagen I and telopeptide-intact rat tail
collagen I (ref. 22). When seeded on atelopeptide bovine collagen,
95% of A375M2 cells are rounded, while in A375P cells the
proportions are B50% rounded, 50% elongated cells (Fig. 1a;
Supplementary Fig. 1a), as quantified using a previously reported
method4,9,18,23–26. Similar results were obtained when cells were
grown on telopeptide-intact collagen, and the differences between
the two cell lines were even enhanced (Supplementary Fig. 1a).We
also quantified roundness from the F-actin-staining images (Fig. 1b),
showing that A375M2 cells are mostly rounded, while A375P are a
mix of both morphologies. In both cell lines, cell rounding was also
associated with membrane blebbing (Fig. 1b), as previously
described19,27. Accordingly, phosphorylated MLC2 (p-MLC2)
levels were nearly twofold higher in A375M2 compared with
A375P cells (Fig. 1c), indicative of higher actomyosin contractility
levels28. We obtained similar results by immunoblot of whole
cell lysates (Fig. 1c) or immunofluorescence in single cells
(Supplementary Fig. 1b). MLC2 phosphorylation levels in the
rounded sub-population within A375P cells were similar to those in
mostly rounded A375M2 cells (Supplementary Fig. 1b).
We therefore decided to use these two cell lines as a good
system to distinguish between rounded-amoeboid and elongated-
mesenchymal cells and to measure secretion of proteases when
cultured on collagen I matrices. We compared media derived
from A375M2 rounded-amoeboid cells with media from A375P
more elongated-mesenchymal cells by performing a MMP-
directed array including soluble MMPs. Unexpectedly, we
observed higher levels of MMP-9 (a gelatinase), MMP-13 (a
collagenase) and MMP-10 (a stromelysin) in media derived from
A375M2 rounded-amoeboid cells compared to A375P cells
(Fig. 1d,e and Supplementary Fig. 1c), and slightly higher levels
of other MMPs. As membrane-tethered MMPs were not included
in the array, we analysed levels of MT1-MMP (MMP-14), but we
could not detect significant changes in MT1-MMP protein levels
when comparing whole lysates of A375M2 and A375P cells
(Supplementary Fig. 1d). Several MMPs have important roles as
activators of other proMMPs29. We performed Network
enrichment analysis using MetaCore with the MMPs present in
the protein array. Such analysis placed MMP-9 in the centre of
this cascade/network of proteases (Fig. 1e).
Matrix remodelling is essential for efficient invasion and it can
be achieved through force-mediated remodelling or via matrix
degradation30. We confirmed that A375M2 expressed higher
levels of the collagenase MMP-13 when compared with A375P
cells (Fig. 1f). Interestingly, A375M2 rounded-amoeboid cells
were surrounded by less collagen I (both atelopeptide and
telopeptide-intact) than A375P cells, as measured by density of
matrix fibres surrounding cells22 (Fig. 1g,h and Supplementary
Fig. 1e). There was a good correlation between roundness and
lack of matrix (Fig. 1i). These effects could be mediated by
actomyosin-mediated force and/or by matrix degradation. We
immunostained for the collagen cleavage neo-epitope COL1-34C to
assess collagenolysis as previously described22,31. COL1-34C
staining surrounding A375M2 rounded cells was higher than
that surrounding A375P cells (Fig. 1j and Supplementary Fig. 1f).
These results show that rounded-amoeboid cells engage in
collagenolysis, and since MMP-13 collagenase is expressed at
higher levels by A375M2 cells (Fig. 1f), most of this degradation
potential is likely due to high MMP-13 secreted levels and would
explain previously reported collagen I degradation by these
cells17.
The largest differences in MMP expression between A375M2
and A375P cells were on MMP-9 levels (Fig. 1d) and MMP-9 is at
the centre of the network interaction map (Fig. 1e). Since MMP-9
is not a canonical collagenase, but rather a gelatinase32,33, we
explored the possibility that MMP-9 could have alternative roles
on cells in collagen I rather than direct degradation of the matrix.
ROCK-JAK-STAT3 regulate MMP-9 in rounded-amoeboid
cells. We confirmed higher levels of MMP-9 secreted by A375M2
compared with A375P-derived media by immunoblot (Fig. 2a
(upper panel) and Supplementary Fig. 2a; fivefold difference).
A375M2 cells on a stiffer matrix increase their actomyosin con-
tractility9 and therefore A375M2 secreted 10 times more MMP-9
on stiff plastic when compared with A375P cells (Fig. 2a (lower
panel) and Supplementary Fig. 2a). Gelatin zymography assays
also confirmed that MMP-9 levels were increased in A375M2
compared with A375P cells (Fig. 2b). MMP-2 was also
upregulated in A375M2 cells (Fig. 2b), which could further
contribute to collagen I degradation.
We expanded these observations to a larger panel of
melanoma cells displaying different degrees of rounding4.
We found a striking positive correlation between the
percentage of rounded cells and MMP-9 mRNA and protein
levels (Fig. 2c–e). MMP-13 and MMP-2 levels also correlated
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with roundness (Supplementary Fig. 2b–d), suggesting that
these rounded-amoeboid melanoma cell lines could also
degrade collagen. We could not find the same degree of
correlation between roundness and MT1-MMP expression, but
both rounded-amoeboid and elongated-mesenchymal melanoma
cells expressed similar levels of MT1-MMP (Supplementary
Fig. 2e).
Rho-ROCK (ref. 6) and JAK-STAT3 (ref. 9) signalling sustains
actomyosin contractility in rounded-amoeboid migrating cells.
We tested whether these signalling pathways were also
responsible for regulating MMP-9 expression, and found that
MMP-9 mRNA and protein levels were reduced after ROCK
inhibitor (H1152), JAK inhibitor (P6) treatment (Fig. 2f) or RNAi
against JAK1 and ROCK1 (Supplementary Fig. 2f,g). All these
treatments decreased cell rounding on collagen (Fig. 2f and
Supplementary Fig. 2f–h). Reduced MMP-9 levels after inhibitor
treatments were also confirmed by zymography (Fig. 2g and
Supplementary Fig. 2h). These results show that MMP-9
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Figure 1 | Rounded-amoeboid cells produce MMPs on collagen matrices. (a) Percentage of rounded and elongated A375P and A375M2 cells on top of
atelopeptide bovine collagen I (manual classification) (600 cells per experiment, n¼4). (b) Cell morphology of A375P and A375M2 cells on top of bovine
collagen I according to ‘roundness’ factor (ImageJ classification): closer to zero more elongated; closer to 1 more rounded. Dots represent single cells from
two independent experiments. Representative confocal images of F-actin staining are shown below. Arrowheads point to blebs. Scale bars, 50 mm (A375P
o0.4), 20mm (A375P40.6 and A375M240.6), 10mm (A375M2 blebs). (c) Representative immunoblot (top) and quantification (bottom) of phospho-
MLC2 (p-MLC2) levels in A375M2 and A375P cells on bovine collagen (n¼ 5). (d) Heatmap for MMP/TIMP levels from A375P versus A375M2 cells on
bovine collagen (n¼ 2). Quantification of pixel density (shown in arbitrary units; mean±s.e.m.) of the levels of each MMP or TIMP in A375M2/A375P is
also shown. Mean of two independent protein arrays is represented. Each array also contains duplicates. (e) MetaCore enrichment analysis showing the
network of secreted MMPs/TIMPs from (d). (f) MMP-13 secreted protein levels in A375P and A375M2 cells on plastic (n¼ 3). Lower panel shows
representative immunoblot. (g) Representative confocal images of A375P and A375M2 cells on atelopeptide bovine and telopeptide-intact rat tail collagen
I. F-actin-staining (red) is shown. ECM fibres are detected from backscattered light/reflectance (grey). Scale bars, 25 mm. (h) Quantification of matrix/
reflectance signal within 5 mm from edge of A375P and A375M2 cells on bovine (left) and rat tail (right) collagen I matrix from (g). Dots represent single
cells from two independent experiments. (i) Quantification of matrix/reflectance signal within 5 mm from edge of cells relative to cell morphology
(roundness) (from h, bovine collagen). (j) Representative confocal images (left) and quantification (right) of collagen cleavage neo-epitope COL1-34C
immunostaining (cyan) within 10mm from edge of A375P and A375M2 cells on bovine collagen I. Collagen I without cells was also stained. F-actin-staining
(red) and reflectance (grey) are shown. Dots represent single cells from two independent experiments. Scale bar, 25mm. Graphs show mean±s.e.m.
*Po0.05, **Po0.01, ***Po0.001, ****Po0.0001. ns, not significant. Unpaired t-test (a–c,f,h,j).
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expression is controlled by actomyosin regulators ROCK and
JAK-STAT3.
MMP-9 positively regulates roundness and MLC2 activity. We
have found a strong correlation between MMP-9 levels and the
degree of cell rounding in collagen I matrices. Since MMP-9 is not
a collagenase per se, we investigated whether its expression could be
induced to regulate functions in rounded-amoeboid cells other
than degrading collagen I. We therefore assessed whether MMP-9
itself could regulate cell morphology and actomyosin contractility
levels in rounded-amoeboid cells. Surprisingly, MMP-9 depletion
in A375M2 cells grown on atelopeptide or telopeptide-intact col-
lagen I caused a significant decrease in cell rounding (associated
with an increase in cell elongation; Fig. 3a,b and Supplementary
Fig. 3a,b). MMP-9 depletion also decreased p-MLC2 levels as
measured by immunoblot of whole-cell lysates (Fig. 3c) or in single
cells by immunofluorescence (Fig. 3d). Similar results were
observed in WM1361 melanoma cells (Supplementary Fig. 3c–e).
Even in A375P cells, which express lower levels of MMP-9 than
A375M2 cells, we could alter the balance from rounded-amoeboid
towards elongated-mesenchymal by decreasing MMP-9 levels
(Supplementary Fig. 3f), indicating that the sub-population of
rounded A375P cells could also use MMP-9 for sustaining
roundness. Importantly, depletion of other MMPs present in the
array, such as MMP-1, MMP-2 or MMP-8 did not regulate cell
morphology in the same manner (Supplementary Fig. 3f), indi-
cating a very specific role for MMP-9.
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(right) of secreted MMP-9 and MMP-2 from A375P and A375M2 cells cultured for 48 h on plastic (n¼ 7). GAPDH from cell lysates is shown. (c) MMP-9
mRNA levels in a panel of melanoma cell lines (relative to A375P) on plastic (n¼ 3) and correlation analysis (Spearman’s r). Percentage of rounded cells on
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Rounded-amoeboid cells secrete MMP-9 (Fig. 2d), but MMPs
can be secreted in a paracrine manner by stromal cells34–36.
Exogenous proMMP-9 added to A375P cells caused an increase
in the rounding index (Fig. 3e–g). We could detect MMP-9
bound to the ECM and bound to the cell surface (Fig. 3e). To
further investigate the possible paracrine actions of MMP-9, we
collected media from A375M2 cells—rich in MMP-9—or media
derived from A375P cells—with lower levels of MMP-9
(Fig. 2a)—and treated A375P cells with both media (Fig. 3h).
We could detect a significant increase in cell rounding and
p-MLC2 levels in A375P cells when treated with A375M2-derived
media. These effects were reduced if A375M2 cells had been
depleted of MMP-9 (Fig. 3i,j).
These results show that MMP-9 secreted by cancer cells can
regulate rounded morphology and p-MLC2 levels in an autocrine
and/or paracrine manner.
MMP-9 function is independent of its catalytic activity. MMP
functions can be dependent or independent of their catalytic
domain37–39. We therefore explored whether a catalytically
inactive MMP-9 mutant40, MMP-9 E402A (Fig. 4a), had any
effect on cell rounding and actomyosin contractility. When
exogenously added to A375P elongated-mesenchymal cells,
MMP-9 E402A derived from HEK293T cells was as efficient as
MMP-9 wild type in regulating cell morphology and p-MLC2
levels in A375P cells (Fig. 4b,c). To further test the effects of
inhibiting MMP-9 catalytic activity on cell morphology and
actomyosin contractility, MMP-9 inhibitor I (refs 40–44) was
used. MMP-9 inhibitor I treatment did not affect cell morphology
or p-MLC2 levels at the concentrations used (Fig. 4d,e). This
concentration range should inhibit MMP-9, as the IC50 of this
inhibitor is 5 nM (ref. 41). To maintain sufficient inhibitory
activity, the employed concentrations of inhibitor were 10–100-
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fold higher than the known maximum inhibitory values, using the
same approach described for other protease inhibitors14. Gelatin
is a bona fide substrate for MMP-9 (ref. 45).To validate MMP-9
inhibitor efficiency at the concentrations used, we performed
gelatin-degradation assays in parallel as a method to measure
MMP-9 enzymatic activity46. We observed that this inhibitor was
efficient at impairing the formation of degradative spots at the
concentrations used (Fig. 4f and Supplementary Fig. 4). These
results show that MMP-9’s catalytic activity is sensitive to MMP-
9 inhibitor, but the inhibitor has no effect on regulating cell
morphology or p-MLC2 levels.
To test the contribution of MMP-9 to amoeboid 3D migration,
we depleted MMP-9 using RNAi in A375M2 rounded-amoeboid
cells and observed a significant reduction in migration through a
3D collagen I matrix, due to decreased actomyosin levels (Fig. 4g).
We then confirmed that the catalytic activity of MMP-9 was not
required for 3D migration of rounded-amoeboid cells into
collagen I, as it was barely affected by MMP-9 inhibitor I
treatment (Fig. 4h) (which had no effects on cell morphology or
p-MLC2 levels; Fig. 4d,e).
These data suggests that MMP-9 is important for the
regulation of cell morphology, p-MLC2 levels and invasion of
rounded-amoeboid cells into collagen I matrices, independently
of its catalytic activity.
MMP-9 regulates rounded-amoeboid migration via CD44.
Since MMP-9 is a secreted protease, MMP-9 could bind to a
membrane receptor—in a paracrine or autocrine fashion—
activating a signalling pathway leading to increased intracellular
actomyosin contractility. We explored whether CD44 could be
such a receptor, as it has been previously described to interact
with MMP-9 in other systems47–49. First we confirmed that
endogenous MMP-9 colocalized with CD44 on the periphery of
A375M2 rounded-amoeboid cells (Fig. 5a,b). Exogenous
proMMP-9 induced cell rounding when added to A375P cells
(Fig. 3f), and it colocalized with CD44 on the cell periphery to the
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same extent as endogenous MMP-9 did in A375M2 cells (mean
colocalization index E0.8; Fig. 5b). Depletion of CD44 in
A375M2 rounded-amoeboid cells resulted in a reduction of cell
rounding in both types of collagen I-atelopeptide and telopeptide-
intact- and decreased p-MLC2 levels (Fig. 5c,d, Supplementary
Fig. 5 and Supplementary Movie 1). After proMMP-9 addition,
CD44-depleted A375P cells did not achieve as much rounding as
control cells (Fig. 5e,f). These effects were associated with a loss of
MMP-9 localization in the cell periphery (Fig. 5e).
These results show that MMP-9 contributes to maintenance of
cell rounding and high p-MLC2 levels via CD44 receptor.
MMP-9 from rounded-amoeboid melanoma cells is important
in vivo. We have previously described an enrichment of rounded-
amoeboid cells in the invasive fronts of melanoma xenografts4, in
the invasive fronts of human primary melanomas9 and in
melanoma metastatic lesions9. To extend our observations
regarding MMP-9 expression and function to the clinical
setting, we analysed MMP-9 protein levels in human melanoma
tumours. We found MMP-9 positive expression in all melanoma
patient samples tested by immunofluorescence (Fig. 6a). We then
defined the tumour invasive front in melanoma patients as
previously described: melanoma cells with at least 50% cell
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surface in contact with the matrix9. In our cohort of patients,
there was an increase in roundness in the invasive front of lesions
(Fig. 6a, bottom left panel), in accordance with previous
morphological assessments in melanoma patients9. For
comparison purposes, fibroblast and lymphocytes were also
quantified (Fig. 6a, bottom left panel). Importantly, we could
detect a further enrichment in MMP-9 protein levels in the
invasive fronts of the melanoma lesions (Fig. 6a, top and bottom
right panels), suggesting a role for MMP-9 in those invasive
fronts. These results show an association between roundness and
MMP-9 expression in vivo in human melanoma patients.
As we found that JAK-STAT3 regulates MMP-9 levels in
rounded-amoeboid cells (Fig. 2f,g), we correlated levels of active
JAK-STAT3 signalling (measured by STAT3 phosphorylation
levels, p-STAT3) and MMP-9 using A375M2 tumour xenografts
in nude mice4,9. All regions positive for p-STAT3 were positive
for MMP-9 (Supplementary Fig. 6). We then used a set of human
melanoma metastatic samples and we found a strong correlation
between MMP-9 and p-STAT3 signal (Fig. 6b). Importantly,
increased staining for p-STAT3 and MMP-9 was observed in the
invasive fronts, while the tumour body from the same lesions
showed less staining (Fig. 6b). These results indicate an
association between MMP-9 expression and active STAT3
in vivo in mice and in human melanoma patients.
Experimental metastasis assays have been widely used to
measure metastatic potential and tail vein injection is an accepted
method to measure the ability of cancer cells to attach to blood
vessels and survive in the lung50–53. The first hours after injection
are crucial to determine successful colonization, as cancer cells
need to adhere to endothelial cells; if cells fail to do this, tumour
cell elimination by apoptotic or other mechanisms is dominant52.
High levels of actomyosin contractility in cancer cells have been
reported to promote efficient lung colonization or
seeding4,21,23,26,52,54,55, and A375M2 cells have been selected to
efficiently colonize the lung21. We wanted to understand whether
MMP-9 via its regulation of actomyosin contractility could
contribute to efficient retention in the lungs in the early steps of
lung colonization, and demonstrate an in vivo role for MMP-9 in
the regulation of actomyosin contractility. Following tail vein
injection in mice, similar amounts of melanoma cells lodged in
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Figure 6 | MMP-9 from rounded-amoeboid melanoma cells is important in vivo. (a) Representative confocal images (top) and quantification (bottom
right) of MMP-9 (green) immunostaining of 8 human melanoma lesions. Nuclei were stained with 40,6-diamidino-2-phenylindole (DAPI, blue). The
confocal images show invasive front and inner regions (tumour body) of the tumour. The dashed line represents the boundary between tumour and stroma.
Scale bars, 35mm (invasive front) and 25 mm (tumour body). Bottom left panel shows cell morphology (roundness) in the invasive fronts of four patients.
Dots represent single cells. Fibroblasts and lymphocytes were also included for comparison purposes. (b) Representative confocal images (top) of MMP-9
(green) and p-STAT3 (red) immunostaining of human melanoma metastatic lesions. Invasive front and inner region (tumour body) are pictured. The
dashed line represents the boundary between tumour and stroma. Scale bars, 75mm (invasive front) and 35 mm (tumour body). Quantification of MMP-9
and p-STAT3 fluorescence signal from four patients (bottom). (c) Representative confocal images (top) of mouse lungs 1 h and 10 h after tail vein injection
of MMP-9-depleted A375M2 cells (CMFDA-Green-stained) (n¼ 3). Scale bar, 100mm. Relative proportions of A375M2 cells in the lungs after MMP-9
depletion 10 h post-tail vein injection (middle). Dots represent single mice from three independent experiments; four mice/condition/experiment. Secreted
MMP-9 immunoblot before injection (bottom). (d–f) MMP-9 expression using normalized microarray gene expression data of (d) Talantov, (e) Riker and
(f) Avery series of melanoma tissues. Graphs show mean±s.e.m. *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001. Unpaired t-test (a,c), ANOVA with
Tukey’s post hoc test (b), Kruskal–Wallis test with Dunn’s post hoc test (d,e), Mann–Whitney test (f).
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the vessels of the lungs 1 h post injection (Fig. 6c, top panel).
However, significantly fewer MMP-9-depleted rounded-
amoeboid A375M2 cells were present in the lungs 10 h after
injection compared with control cells (Fig. 6c). We could not co-
inject control and MMP-9-depleted cells together as previously
described by our lab and others4,9,23,55, due to the paracrine
effects of MMP-9 (Fig. 3e–j). These results could indicate that
MMP-9 secreted by amoeboid cancer cells helps in successful
retention in the lungs in vivo by promoting actomyosin
contractility.
We have shown so far that MMP-9 regulates invasion (Fig. 4g)
and early steps in lung colonization of amoeboid melanoma cells
(Fig. 6c). We investigated whether MMP-9 could be regulated
during melanoma progression. Since we have found that MMP-9
is regulated via JAK-STAT3 at the mRNA level (Fig. 2f), we
analysed MMP-9 mRNA at different stages of melanoma
progression56–58, utilizing published data from gene expression
analysis (from public database Gene Expression Omnibus (GEO))
from purified human melanomas samples that would exclude the
stromal contribution (see Methods). We only took into account
published studies with enough sample purity (495% melanocytic
cells), enough patient samples to perform statistical comparisons
(n440); and studies including normal tissue. From the Talantov
study (Fig. 6d), we found increased MMP-9 in primary
melanomas compared with normal skin and naevus. Using the
Riker study (Fig. 6e), we found augmented MMP-9 in primary
melanomas and in metastatic tissue compared with normal skin.
From the Avery study (Fig. 6f), we found increased MMP-9 in
metastatic versus melanocytic samples. These data suggest that
there is an overall upregulation of MMP-9 expression levels
during melanoma progression (Table 1).
Discussion
We have described how rounded-amoeboid melanoma cells show
higher expression levels and higher secretion of a number of
MMPs when compared with elongated-mesenchymal cells. In
particular, we show that MMP-13, MMP-2 and MMP-9 are
associated with rounded-amoeboid cell morphology in a panel of
12 melanoma cell lines. MMP-13 and MMP-2 could be
responsible for collagen I degradation in rounded-amoeboid cells
as we have shown in Fig. 1 for A375M2 cells. On the other hand,
MMP-9 is acting as a signalling intermediate to activate MLC2
phosphorylation and efficient amoeboid 3D migration (Fig. 7).
We have also shown that MMP-9 expression is regulated by
ROCK and JAK-STAT3. MMP-9 promoter contains several
putative STAT3-binding sites, two of which can be considered of
high affinity59. We propose here that the transcriptional
mechanism by which amoeboid cells are capable of sustaining
high levels of MMP-9 is through high JAK-STAT3 signalling, a
pathway that is activated in rounded-amoeboid cells9.
We demonstrate that MMP-9 regulates rounded-amoeboid cell
migration through regulation of actomyosin contractility via
CD44 (Fig. 7), a receptor for hyaluronic acid and collagen60, and
which is frequently upregulated in cancer61. MMP-9 is a key
regulator of growth factor processing that may lead to the
activation of migration-enhancing cytokines and growth
factors32. We do not exclude this mechanism of action and
further work is needed to address the possible contribution to
amoeboid migration of MMP-9 catalytic activity in releasing
active cytokines, chemokines, growth factors or their
receptors32,62. However, a role of such a mechanism in
regulating actomyosin contractility might not be strictly
necessary since we have found that MMP-9 inhibitor did not
affect cell morphology and p-MLC2 levels in our experimental
setting.
MMP-9 secreted in a paracrine manner by cancer cells with
high STAT3 signalling promotes actomyosin-driven amoeboid
strategies. MMP-9 has been described to be secreted by
macrophages34 and endothelial cells63. Since MMP-9 can act in
a paracrine manner (Fig. 3e–j), it is possible that stromal sources
of MMP-9 (ref. 64) contribute to regulate actomyosin
Table 1 | MMP-9 mRNA expression in gene expression
studies on melanoma progression.
Fold change in MMP-9 mRNA expression
Study Primary/normal Primary/naevus Metastasis/normal
Talantov 3.54 3.02
Riker 10.21 30.66
Avery 3,928.022
Table shows the fold change in MMP-9 mRNA expression when comparing its average
expression in primary melanoma (primary) versus normal tissue (normal) or naevus, and in
metastatic melanoma (metastasis) versus normal tissue. Data is from Fig. 6d–f.
Extracellular matrix
Rounded-amoeboid
invasion
MMP-13
CD44
MMP-9
Actomyosin
contractility 
p-STAT3
Rho/ROCK
MLC2
JAK
MMP-9
Blebs
?
Stromal cell
Rounded-amoeboid
melanoma cell
MMP-9
Figure 7 | MMP-9 regulates amoeboid migration in a catalytic independent manner. Model summarizing MMP-9 functions in rounded-amoeboid cells.
MMP-9 contributes to generation of actomyosin contractility via CD44 binding and increased MLC2 phosphorylation, which leads to increased p-STAT3
and higher MMP-9 expression and secretion, generating a positive feedback loop that self-sustains rounded-amoeboid invasion. In addition, rounded-
amoeboid cells secrete other MMPs such as MMP-13 that could contribute to matrix degradation. Stromal cells could also contribute to the pool of
secreted MMP-9.
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contractility in cancer cells in vivo. The paracrine actions of
MMP-9 regulating amoeboid strategies in cancer cells could be
relevant in the invasive fronts of tumours, in close contact with
immune cells, or in blood vessels, where cancer cells interact with
endothelial cells.
On the other hand, MMP-9 non-catalytic functions are
essential to promote cancer cell survival in chronic lymphocytic
leukaemia patients39. Our results regarding tumour cell-derived
MMP-9 promoting lung retention could also indicate a role of
MMP-9 in the survival of amoeboid cells in the early steps of
colonization.
Different environments may favour different strategies of
migration and invasion. High actomyosin contractility can be
used to achieve high migration speeds in vivo4,8,19,55. When
pericellular proteolysis is ablated, cells may just use their
actomyosin contractility in order to move and remodel the
matrix6,14 up to the limitations of the pore size in the ECM22,65.
In this respect, we show here that when actomyosin contractility
is very high in cancer cells, they can indeed increase expression/
secretion of some MMPs to sustain actomyosin levels (MMP-9)
or collagen degradation (MMP-13, MMP-2).
In summary, MMP-9 could be an amoeboid-selective marker
for melanoma, and blocking MMP-9 non-catalytic functions
could be a good strategy to reduce invasion and metastasis of
rounded-amoeboid cancer cells.
Methods
Antibodies and inhibitors. Antibodies and dilutions used: MMP-9 (Clone 4H3,
MAB911; 1:1,000), MMP-13 (MAB511; 1:500) from R&D Systems; pSer19-MLC2
(immunofluorescence; 1:200), pThr18/Ser19-MLC2 (immunoblotting, 1:750) and
pY705-STAT3 (1:750) from Cell Signaling Technology (no. 3671, no. 3674 and no.
9145, respectively); STAT3 (sc-482; 1:500) and MLC2 (sc-15370; 1:200) from Santa
Cruz Biotechnology; ROCK1 (611137; 1:1,000) from BD Transduction; GAPDH
(MAB374; 1:10,000) from Millipore; CD44 (Clone IM7, ab119863; 1:2,000) from
Abcam; MT1-MMP (SAB4501901; 1:1,000) from Sigma; affinity-purified antibody
COL1-34C (no. 0217-050, Immunoglobe; 1:50) directed against the C-terminal
cleavage neo-epitope of collagen types I and II (refs 22,31).
ProMMP-9 (2–4 mgml 1, no. PF038), P6 (1–10 mM), H1152 (5 mM) and
MMP-9 inhibitor I (0.05–1 mM) were from Calbiochem (Nottingham, UK); Y27632
(10 mM) from Tocris Bioscience (Bristol, UK).
Cell culture. A375P and A375M2 melanoma cells were from Dr Richard Hynes
(HHMI, MIT, USA). CHL, SKMEL28, 501MEL, SKMEL2, SKMEL23, WM266.4,
SBCL2, WM1361, WM1366 and WM3670 melanoma cells were from Professor
Richard Marais (Cancer Research UK Manchester Institute, Manchester, UK).
HEK293T cells were from Dr Jez Carlton (King’s College London). Cells were
maintained in DMEM (RPMI for WM1361, SBCL2 and WM3670) containing 10%
fetal calf serum (FCS). Since melanoma cells cultured for long periods tend to lose
their amoeboid properties, cells were kept in culture for a maximum of 3–4
passages.
Cell culture on thick layers of collagen I. Atelopeptide fibrillar bovine dermal
collagen (no. 5005-B; PureCol, Advanced BioMatrix) was prepared at 1.7mgml 1
in DMEM: 100 ml per well in 96-well plates; 300ml per well in 24-well plates, 700 ml
per well in 12-well plates. Telopeptide-intact rat tail collagen (no. 5153-A; PureCol,
Advanced BioMatrix) was prepared at 0.5mgml 1 following the manufacturer’s
instructions (700 ml per well in 24-well plates). Bovine collagen gels at 1.7mgml 1
and rat tail collagen gels at 0.5mgml 1 have comparable stiffness, pore diameter
and pore cross section as previously described22. After collagen gel polymerization
(4 h for bovine collagen, 2 h for rat tail collagen), cells were seeded on top of
collagen in medium containing 10% FCS, allowed to adhere for 24 h and medium
changed to 1% serum for 24 h. Except where indicated, imaging and
immunoblotting were performed on cells cultured on a thick layer of collagen I.
ProMMP-9 treatments. For ProMMP-9 treatment experiments, A375P cells
were seeded on collagen and, on the following day, washed and treated with
2–4 mgml 1 ProMMP-9 dissolved in 1% FCS-containing medium for 24 h.
Control cells were treated with solvent (150mM NaCl, 50mM Tris–HCl (pH 7.5),
10mM CaCl2, 0.05% BRIJ-35 Detergent) in 1% FCS-containing medium.
Transfection and RNAi. For melanoma cells, 2 105 cells were plated per 35-mm
dish and transfected the next day with 20–40 nM SmartPool (SP) or individual OTs
(On Targetplus) siRNA oligonucleotides, using Optimem-I and Lipofectamine
2000 (Invitrogen). Forty eight hours after transfection cells were seeded on collagen
in 10% FBS, the next day media was changed to 1% FCS and cells analysed 24 h
later.
RNAi sequences. All siRNA sequences were from Dharmacon (Lafayette, USA),
except otherwise stated: JAK1 no. 1 (Dharmacon siGENOME-08: 50-CGGAUGA
GGUUCUAUUUCA-30); MMP-1 no. 1 (SP 50-AGAAUGUGCUACACGGAU
A-30 , 50-ACAGUAAGCUAACCUUUGA-30 , 50-GAACUCGGCCAUUCUCUU
G-30 , 50-AAAGGUGGACCAACAAUUU-30); MMP-2 no. 1 (SP 50-ACAAGAACC
AGAUCACAUA-30 , 50-GGAAUGCCAUCCCCGAUAA-30 , 50-GCGAGUGGAU
GCCGCCUUU-30 , 50-UCAAGGACCGGUUCAUUUG-30); MMP-8 no. 1 (SP 50-G
CAAUAAAUGGCUUAACUG-30 , 50-GGAGAUAUGAUAACCAAAG-30 , 50-GU
AUACAGGCUGCUUAUGA-30 , 50-CUACAGGAUUCGAAACUAU-30); MMP-9
no. 1 (SP 50-GGAACCAGCUGUAUUUGUU-30 , 50-AAACUACUCGGAAGACU
UG-30 , 50-GAAUACCUGUACCGCUAUG-30 , 50-GCAUAAGGACGACGUGAA
U-30); MMP-9 no. 2 (OT no. 7 50-GCAUAAGGACGACGUGAAU-3;); MMP-9
no. 3 (OT no. 8, 50-GGACCAAGGAUACAGUUUG-30); CD44 no. 1 (published in
ref. 66, 50-GUAUGACACAUAUUGCUUC-30); CD44 no. 2 (50-UGUGCUACUG
AUUGUUUCA-30 ; this sequence was a gift from Dr Ester Martin-Villar, Instituto
de Investigaciones Biomedicas, CSIC-UAM Madrid, Spain); CD44 no. 3
(Dharmacon OT no. 6, 50-GAAUAUAACCUGCCGCUUU-30); ROCK1
(Dharmacon OT-SP, 50-GCCAAUGACUUACUUAGGA-30, 50-CCAGGAAGGUA
UAUGCUAU-30, 50-UAGCAAUCGUAGAUACUUA-30 and 50-CUACAAGU
GUUGCUAGUUU-30).
MMP-9-encoding plasmids. Vector encoding human MMP-9 cDNA was from
Origene (SC116989). In order to generate the catalytically inactive MMP-9 E402A
mutant, a point mutation changing glutamate 402 into alanine in the catalytic
centre of human MMP-9 was inserted by PCR using QuikChange (Stratagene) and
the pair of primers: 50-TGGCGGCGCATGCGTTCGGCCACGC-30 and
50-GCGTGGCCGAACGCATGCGCCGCCA-30(underline denotes mutated base)
as described before40. For plasmid transfections into HEK293T cells, 1 mg plasmid
(empty vector, MMP-9 wild type or MMP-9 E402A) per 35-mm dish was used.
The following day, HEK293T cells were carefully washed and cultured in 1% FCS-
containing medium for 24 h. Then, media were collected, spun down to remove cell
debris, diluted 1:2 with 1% FCS-containing medium and added to A375P already
on collagen I (seeded on collagen 24 h earlier). A375P were cultured in transfected
HEK293T-derived media for 20 h and then cell morphology was assessed as
described above. Aliquots of the fresh HEK293T-derived media were analysed by
gelatin zymography and immunoblotting (see below) to assess MMP-9 activity and
expression.
Time-lapse phase-contrast microscopy. Multi-site bright-field microscopy of
cells in 12-well plates containing thick layers of collagen and evaluation of per-
centage of elongated/rounded cells was performed as described previously4.
Imaging was performed in a humidified chamber at 37 C and 5% CO2 using a
 10/0.3 NA Plan Fluor ELWD objective lens on a fully motorized (Prior
Scientific) multi-field Nikon TE2000 microscope with an ORCA camera
(Hamamatsu) controlled by MetaMorph (Molecular Devices) and Volocity (Perkin
Elmer) software.
3D migration assays. Cells were suspended in serum-free bovine collagen I at
2.3mgml 1 to a final concentration of 10 103 cells per 100 ml and processed as
previously described4. Cells were mixed with collagen, seeded on 96-well plates,
spun down and 4 h later 5% FCS-containing media was added on top of the gel,
allowing the cells to invade upwards for 24 h. Then cells were fixed in 4%
formaldehyde for 16 h and stained with 5 mgml 1 Hoechst 33258 (Molecular
probes–Life Technologies). Plates were imaged on a Zeiss LSM 510 Meta confocal
microscope (Carl Zeiss, Germany) with a Plan Apochromat  10/0.30 objective
lenses and Zen software (Carl Zeiss; see below section ‘Confocal fluorescence
microscopy and image quantification’ for more details). Confocal z-slices were
collected from each well at the bottom of the well (1mm) and at 50mm. Samples
were run in quadruplicate and averaged. The 3D migration index was calculated as
number of invading cells at 50 mm divided by the total number of cells.
Immunoblotting. Cells were lysed in Laemmli sample buffer and sonicated for 15 s
before centrifugation. For secreted proteins, media was collected and spun down to
remove debris. Cell lysates or secreted media were fractionated using precast 4–12%
gradient SDS–polyacrylamide gel electrophoresis (SDS–PAGE) gels (Life Technol-
ogies) in non-reducing conditions, and transferred subsequently to PVDF filters. To
detect MMP-13, conditioned media was concentrated (5–10 times) using Amicon
Ultra-0.5ml 10 kDa cutoff centrifugal devices (Millipore) following the manu-
facturer’s instructions. The ECL Plus or Prime ECL detection Systems (GE
Healthcare) with HRP-conjugated secondary antibodies (GE Healthcare) were used
for detection. When detecting secreted proteins, GAPDH from the cell lysates was
also analysed to show equivalent cell numbers. Bands were quantified using Image J
(http://rsb.info.nih.gov/ij/). When calculating phospho-MLC2 levels, total MLC2 was
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used for normalization. Note that proteins run at higher molecular weight than
expected when using these gels and the Rainbow molecular weight marker (GE
Healthcare). For example, the predicted molecular weight for MLC2 is 18 kDa, while
in our conditions it runs above the 24-kDa marker, at B30 kDa. The predicted
molecular weight for MMP-9 is 82–92 kDa, while in our conditions it runs closer to
the 102-kDa marker. Full blots are provided in Supplementary Figs 7 and 8.
Matrix metalloproteinase protein array. MMP levels were measured using
RayBio Human Matrix Metalloproteinase Antibody Array (AAH-MMP-1, Ray-
Biotech, Inc.). Cells were seeded on top of collagen in 10% FCS-containing med-
ium, allowed to adhere for 24 h and then grown in serum-free medium for 48 h.
Media were collected, spun down to discard debris and probed onto the protein
array membranes following the manufacturer’s instructions. Chemiluminescence
signal was further analysed using the Protein Array Analyzer plugin for ImageJ
(http://image.bio.methods.free.fr/ImageJ/?Protein-Array-Analyzer-for-Ima-
geJ.html). Heatmaps were generated using MultiExperiment Viewer software
(Microarray Software Suite, http://www.tm4.org/mev.html). MMP/TIMP networks
were analysed using MetaCore (Thomson Reuters, http://thomsonreuters.com/
metacore/).
Gelatin zymography. Gelatin zymography was performed following standard
protocols67. Secreted serum-free medium from cells grown on plastic for 48 h was
loaded on 10% SDS-PAGE gels containing 1mgml 1 gelatin (Sigma) in non-
reduced protein sample buffer. Following electrophoresis, SDS was washed out by
incubating the gels in 2.5% Triton X-100 for 30min at room temperature. Gels
were then washed three times in distilled water and incubated in substrate buffer
(50mM (Tris pH 7.4), 200mM NaCl, 2mM CaCl2, 1mM MgCl2) at room
temperature for 30min and then at 37 C for 16 h. Gels were stained with 0.5%
Coomassie Blue R-250 (Sigma) and destained in 5% methanol and 10% acetic acid.
Enzymatic activities appear as cleared bands in a dark background. In melanoma
cells, MMP-9 82-kDa form was detected just right above the 76-kDa marker, while
MMP-2 62-kDa form was detected above the 52-kDa marker. In MMP-9-
overexpressing HEK293T cells, only the MMP-9 82-kDa form was detected. Bands
were quantified using Image J. Full zymography gels are provided in
Supplementary Figs 7 and 8.
Gelatin-degradation assays. Gelatin-degradation assays were performed as pre-
viously described46. In brief, glass coverslips were coated with rhodamine-gelatin
(2mgml 1), crosslinked with 0.5% glutaraldehyde and quenched with 10% FCS-
containing medium overnight at 37C. CMFDA-Green-labelled cells (10mM, Life
Technologies) were pretreated with MMP-9 inhibitor I (or DMSO vehicle) for 16 h,
then harvested and seeded onto the gelatin-coated coverslips in the presence of
MMP-9 inhibitor I/vehicle for 6 h. Afterwards, cells were fixed with 4%
formaldehyde and analysed for gelatin-degradation under a confocal microscope.
Gelatin-degradation spots were quantified using ImageJ.
Confocal fluorescence microscopy and image quantification. Cells were seeded
on top of a collagen I matrix in glass-bottomed dishes (MatTek, Ashland, MA,
USA) and immunostained as described27. Cells were fixed (4% formaldehyde),
permeabilized (0.2% Triton X-100; except for MMP-9 and COL1-34C
immunostaining, in which cells were not permeabilized), blocked in 5% bovine
serum albumin (BSA) and immunostained with specific antibodies diluted in 5%
BSA, which were detected with secondary Alexa Fluor 488, 546 or 647 antibodies
(Life Technologies). F-actin was stained using Alexa Fluor 546- or 647-phalloidin
(Life Technologies). Imaging was carried out on a Zeiss LSM 510 Meta confocal
microscope (Carl Zeiss) with C-Apochromat  40/1.2 NA (water) or a Plan
Apochromat  63/1.4 NA (oil) objective lenses and Zen software (Carl Zeiss).
Backscattered light (reflectance) was collected to image the matrix surrounding
cells. Confocal z-slice images were analysed using ImageJ. For cell morphology, the
shape descriptor ‘roundness’ in ImageJ was used after manually drawing around
the cell shape using F-actin-staining images. Phospho-MLC2, CD44 and MMP-9
fluorescence signal was quantified calculating the pixel intensity in single cells
relative to the cell area. Reflectance/matrix signal within 5 mm from the edge of
single cells was quantified in single cells and calculated relative to the cell
perimeter. For measurement of collagen degradation, COL1-34C fluorescence signal
within 10mm from the edge of single cells was quantified and calculated relative to
the cell perimeter. Colocalization analysis was performed in single cells using the
colocalization tool and the Costes coefficient (automatic threshold)68 in Volocity
software (Perkin Elmer), and the line scan analysis in ImageJ.
Quantitative real time one-step PCR. QuantiTect Primer Assays (Qiagen) and
Brilliant II SYBR Green QRT-PCR 1-step system (Agilent Technologies) were used
following the manufacturer’s instructions. GAPDH was used as loading control.
The following primers were used (Qiagen): GAPDH (QT00079247), MMP-1
(QT00014581), MMP-2 (QT00088396), MMP-9 (QT00040040), MMP-13
(QT00001764), MMP-14 (QT00001533) and JAK1 (QT00050225). However, pri-
mer sequences are not provided by Qiagen, as stated in their website: ‘Sequences of
the QuantiTect Primer Assays are not provided. Approximate location of primers
within a specific gene can be viewed on the Product Detail pages retrieved via our
GeneGlobe data base.’
Analysis of MMP-9 expression from human databases. Gene expression data of
human melanoma samples from published microarray studies was used to analyse
MMP-9 in melanoma progression. We only took into account studies with enough
sample purity (495% melanocytic cells), enough patient samples to perform sta-
tistical comparisons (n440) and studies including normal tissue. From public
database GEO we extracted the Talantov (GEO Accession number GSE3189)58,
Riker (GEO Accession number GSE7553)57 and Avery (GEO Accession number
GSE29359)56 series. Samples from these studies were reported to have 495%
melanocytic/melanoma cells and no mixed histology. Data were normalized using
Gene Pattern (http://www.broadinstitute.org/cancer/software/genepattern/) and
analysed as described in the ‘Statistical analysis’ section below.
Animal welfare. All animals were maintained under specific pathogen-free con-
ditions and handled in accordance with the Institutional Committees on Animal
Welfare of the UK Home Office (The Home Office Animals Scientific Procedures
Act, 1986). All animal experiments were approved by the Ethical Review Process
Committee at King’s College London and carried out under licence from the Home
Office, UK.
Lung retention assays. Forty-eight hours after transfection, A375M2 cells were
labelled with 10 mM CMFDA-Green (Life Technologies), trypsinized and injected
into the tail vein of BALB/c RAG2 /gc / mice (male and female between 6–
12 weeks old (The Jackson Laboratory); mice were age- and sex-matched between
the groups) together with human monocytes (previously shown to enhance lung
retention of cancer cells69), 1 106 A375M2 and 1 106 monocytes in 0.2ml PBS.
Mice were killed after 1 h (to show that equal numbers arrive at the lung) and 10 h,
the lungs were washed, fixed (4% formaldehyde for 16 h) and examined for
fluorescently labelled cells under a confocal microscope (see above). Lung retention
is represented as fluorescence signal (CMFDA-Green from melanoma cells) per
field, andB20 fields per mouse were analysed. Each experiment had four mice per
condition, and experiments were replicated three times. RosetteSep Human
Monocyte Enrichment Cocktail (StemCell Technologies no. 15028) was used to
purify human monocytes.
Tumour xenografts. Female CD1 nu/nu mice (6–10 weeks old; Charles River)
were injected subcutaneously into the flanks with 2 106 A375M2 cells in 0.1ml
PBS and killed after 45 days, when tumours reached B1,000mm3. Tumours were
excised, fixed and paraffin-embedded.
Human sample collection and patient information. Patients were staged and
classified according to the American Joint Committee on Cancer Melanoma Sta-
ging and Classification criteria70. Human samples were collected with informed
written consent, in accordance with the Helsinki Declaration, and the study design
was approved by the Ethics Committees of the Institute of Cancer Research, the
Royal Marsden Hospital Foundation Trust, Guy’s Research Ethics Committee and
Guy’s and St Thomas’ NHS Foundation Trust, in accordance with the Human
Tissue Act, 2004. Supplementary Table 1 shows raw data from human melanoma
patients whose samples were immunostained for MMP-9 and phospho-STAT3.
Immunofluorescence in xenografts and human melanoma samples. Six-
micrometre sections of formalin-fixed, paraffin-embedded material were used.
Slides were dewaxed and antigen retrieval was performed using citrate buffer (pH
6) followed by blocking in PBS-Tween 0.1% þ 1% BSA for 15min and overnight
incubation with MMP-9 and phospho-STAT3 antibodies (1:50 in PBS þ 1% BSA).
Antibody detection was performed using Alexa Fluor-conjugated secondary anti-
bodies (Life Technologies). Slides were counterstained with DAPI. Samples were
analysed and pictures were taken using a Leica SP2 confocal scanning microscope
(Leica Microsystems). The tumour invasive front was defined as the region of the
tumour composed by only melanoma cells with at least 50% cell surface in contact
with the matrix9. For quantification of immunostaining of MMP-9 and p-STAT3
in human melanoma, ImageJ was used to measure fluorescence signal from the
tumour body, invasive front and stroma and then it was calculated relative to the
area selected. MMP-9 data in Fig. 6a are from stainings of patients 1–8. p-STAT3
data in Fig. 6b are from patients 1–4. Quantification of cell morphology (roundness
using ImageJ) in Fig. 6a (middle panel) was performed on H&E stainings from
patients 5–8.
Statistical analysis. Unpaired two-tailed Student’s t-test, Mann–Whitney’s test,
one-way ANOVA with Tukey post test (for multiple comparisons) and Spearman
correlation were performed using GraphPad Prism (GraphPad Software, San
Diego, California, USA; www.graphpad.com), see end of each figure legend for
details. Error bars are ± s.e.m. (*Po0.05, **Po0.01, ***Po0.001, ****Po0.0001,
ns not significant).
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